I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Associate Director/Director, Quality Management Systems

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRemote in USA$160k - $210k /yr

About the Job

Requirements

  • A bachelor's degree in a scientific, engineering, or related discipline, or equivalent experience.
  • 10+ years of pharmaceutical or biotechnology experience, including 7+ years in Quality Assurance and 3+ years owning QMS processes; 12+ years and prior people leadership for the Associate Director level.
  • Hands-on experience running deviations, investigations, CAPA, change control, document control, and GxP training in a GMP environment.
  • Experience implementing or administering an electronic quality management system and applying computer system validation/computer software assurance principles, including 21 CFR Part 11 and EU Annex 11 requirements.
  • Strong knowledge of 21 CFR 210/211, EU GMP, and ICH Q7, Q9(R1), and Q10.
  • Experience managing quality in an outsourced model with contract development and manufacturing organizations, contract research organizations, and contract laboratories.
  • Ability to operate strategically and hands-on in a lean, international matrix organization.
  • Ability to travel up to 15% for partner audits and inspections.

Responsibilities

  • Own and mature the GxP quality management system.
  • Help with commercial-readiness gap assessment and roadmap against FDA, EU GMP, and ICH Q9(R1)/Q10 expectations ahead of NDA submission and pre-approval inspection, as needed.
  • Own quality event management end to end, including deviations, OOS/OOT results, laboratory and partner-reported events, investigations, and root cause analysis; ensure timely triage, risk assessment, and escalation.
  • Own the CAPA and change control processes, including effectiveness checks, and trend quality events across sites and partners to identify and resolve systemic issues.
  • Lead the GxP training program, including role-based curricula, training matrices, LMS/eQMS administration, and compliance metrics; link training to investigation outcomes and retraining effectiveness.
  • Own the computer system validation program and drive the transition to risk-based computer software assurance aligned with 21 CFR Part 11, EU GMP Annex 11, GAMP 5, and FDA CSA guidance.
  • Lead selection, implementation, and validation of an electronic quality management system and serve as its business system owner; partner with IT to validate launch-critical systems.
  • Own document control and help build commercial quality processes such as APR/PQR, complaint handling, and recall procedures.
  • Champion data integrity (ALCOA+) across paper and electronic records, including audit trail review, periodic system review, and data integrity risk assessments.
  • Work on inspection readiness, including mock inspections and subject matter expert preparation, as needed; support regulatory inspections, partner audits, and the internal audit program through closure of commitments.
  • Define QMS metrics and present Quality Management Review inputs to leadership.
  • Lead, coach, and develop QMS staff and consultants as the function grows.
  • Perform other work as assigned by leadership.

Desired Qualifications

  • Experience supporting a pre-approval inspection or a company's transition from clinical to commercial.
  • An advanced degree or ASQ certification (CQA, CQE, or CMQ/OE).
  • Experience with an electronic quality management system.
  • Experience with small-molecule oral solid dosage products.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs